the benefits nonhormonal contraceptive is recommended. Consider therapy modification ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. Monitor therapy Rufinamide: May decrease the serum concentration of Ethinyl Estradiol. Consider therapy modification Saquinavir: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction. Consider therapy modification Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy Selegiline: Estrogen Derivatives (Contraceptive) may increase the serum concentration of Selegiline. Monitor therapy Selegiline: Progestins (Contraceptive) may increase the serum concentration of Selegiline. Monitor therapy Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy St John's Wort: May diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible. If this combination is used foremost
imagined to aceptive failure is possible. Use of an alternative recently
EmoticonEmoticon